摘要
目的比较帕利哌酮与奥氮平治疗精神分裂症疗效和不良反应。方法将86例符合ICD-10诊断标准的精神分裂症患者随机分组,分别给予帕利哌酮或奥氮平单一抗精神病药物治疗,观察期共8周,采用疗效及PANSS、TESS评分评估其疗效及副反应。结果 8周末时,帕利哌酮、奥氮平的治疗有效率、PANSS量表减分率及TESS评分减分率均无显著性差异(P>0.05),帕利哌酮的锥体外系副反应、血清泌乳素水平均明显高于奥氮平,而奥氮平引起的嗜睡、体重增加高于帕利哌酮,差异均有显著统计学意义。结论帕利哌酮与奥氮平治疗精神分裂症的疗效相当,总体副反应少、安全性高,二者副反应有所差异。
OBJECTIVE To compare the efficacy and safety of paliperidone and olanzapine in treating patients with schizophrenia. METHODS Eighty-six patients with schizophrenia met the ICD-10 criteria were randomly allo- cated into two groups,treated with paliperidone or olanzapine for 8 weeks respectively. PANSS scale and Treatment E- mergent Side-effect Scale （TESS）were used to evaluate efficacy and adverse effect respectively. RESULTS Paliper- idone showed equally efficacy （77% Vs 81% ,P = 0. 596）to olanzapine. There were no significant differences in PANSS scores reductions or TESS scores between the two groups. Paliperidone treatment resulted in lower combina- tions of weight-gain and drowsiness than olanzapine, while higher condietions in extrapyramidal side effects and hy- perprolactinmia. CONCLUSION The results suggested that Paliperidone was as effective and safe as olanzapine in treating schizophrenic patients.
出处
《海峡药学》
2016年第9期93-95,共3页
Strait Pharmaceutical Journal
